Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioCardia

2.08
-0.0400-1.89%
Post-market: 2.080.00000.00%19:46 EDT
Volume:37.81K
Turnover:79.56K
Market Cap:10.77M
PE:-0.72
High:2.17
Open:2.17
Low:2.08
Close:2.12
Loading ...

BioCardia Inc. President and CEO Peter Altman Acquires Common Shares

Reuters
·
31 May

Peter Altman, President and CEO, Reports Acquisition of BioCardia Inc. Common Shares

Reuters
·
17 May

Analysts Are Bullish on Top Healthcare Stocks: Akero Therapeutics (AKRO), BioCardia (BCDA)

TIPRANKS
·
15 May

BioCardia Q1 EPS $(0.59) Misses $(0.39) Estimate

Benzinga
·
15 May

BioCardia Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
13 May

BioCardia Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
09 May

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing Cardiamp HF Ii Pivotal Study

THOMSON REUTERS
·
06 May

Biotech Alert: Searches spiking for these stocks today

TipRanks
·
02 May

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind Cardiamp HF Ii Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

THOMSON REUTERS
·
01 May

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

GlobeNewswire
·
01 May

BioCardia files to sell 813,636 shares of common stock for holders

TIPRANKS
·
01 May

Director Richard M. Krasno Reports Acquisition of Common Shares of BioCardia Inc

Reuters
·
29 Apr

BRIEF-Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial

Reuters
·
15 Apr

BioCardia’s CardiALLO Trial Advances After Safety Review

TIPRANKS
·
15 Apr

BioCardia Announces Positive Dsmb Review of Cardiallo Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

THOMSON REUTERS
·
15 Apr

BioCardia Inc: Plans to Progress Trial to Enrollment of 39 Participants in United States

THOMSON REUTERS
·
15 Apr

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

GlobeNewswire
·
15 Apr

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial

MT Newswires Live
·
12 Apr

BRIEF-Biocardia Initiates Patient Enrollment At Emory University School Of Medicine

Reuters
·
11 Apr

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing Cardiamp HF Ii Pivotal Study

THOMSON REUTERS
·
11 Apr